New drug PM54 enters human testing for Hard-to-Treat cancers
NCT ID NCT05841563
First seen Sep 30, 2025 · Last updated May 21, 2026 · Updated 33 times
Summary
This early-phase study tests a new drug called PM54 in about 125 adults with advanced solid tumors that have not responded to standard treatments. The first part finds the safest dose by watching for side effects; the second part checks if the drug can shrink tumors. The goal is to control the disease, not cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
HM Universitario Sanchinarro
RECRUITINGMadrid, M, 28050, Spain
Contact
-
Institut Jules Bordet
RECRUITINGAnderlecht, 1070, Belgium
Contact
-
South Texas Accelerated Research Therapeutics
RECRUITINGSan Antonio, Texas, 78229-3307, United States
Contact
Conditions
Explore the condition pages connected to this study.